ONO Linked In 1120 x 325 px

ONO Pharmaceutical 2024 Golden Ticket

May 24, 2024

Share :

LabCentral 700

Ono Pharmaceutical is inviting life sciences start up companies to apply for their 2024 LabCentral Golden Ticket! ONO will award one promising start-up company with a $50,000 credit towards space and services available at LabCentral's flagship site at 700 Main Street in Cambridge for use within a 13-month period, beginning upon receipt.

ONO is keen to see emerging open innovations in the life science field, which would have potential synergy with its current and future R&D activities. To learn more about ONO Pharma's R&D philosphy, visit their website here us here.

Here’s what you can expect with an ONO - LabCentral Golden Ticket award:

  • $50,000 credit towards space available at LabCentral
  • Access to the shared amenities and services provided at LabCentral
  • Working closely with ONO's R&D scientists, business leaders and global network partners.

To apply, send your non-confidential company presentation, as a PDF, to by May 24th, 2024.

Once submitted, your company’s proposal will be reviewed by ONO’s internal committee and finalist companies will be notified, and invited to present to ONO using a web-meeting system in July 2024. The winner will be notified soon thereafter and presented with the awards.

About Ono Pharmaceutical Co., Ltd.

Ono Pharmaceutical Co., Ltd., headquartered in Osaka Japan, is an R&D-oriented pharmaceutical company committed to creating innovative medicines in specific areas. ONO focuses its research on the oncology, immunology, neurology and specialty area with high medical needs as priority areas for discovery and development of innovative medicines. For further information, please visit the company’s website at here.